These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 1037358)
1. [HLA B8 and Graves' disease (author's transl)]. Jaffiol C; Seignalet J; Baldet L; Robin M; Lapinski H; Mirouze J Ann Endocrinol (Paris); 1976; 37(4):219-26. PubMed ID: 1037358 [TBL] [Abstract][Full Text] [Related]
2. [Study of the HL-A system in Basedow's disease (author's transl)]. Jaffiol C; Seignalet J; Baldet L; Robin M; Lapinski H; Mirouze J Ann Endocrinol (Paris); 1976; 37(2):111-2. PubMed ID: 1036872 [TBL] [Abstract][Full Text] [Related]
3. [HLA DRW3 and Graves' disease (author's transl)]. Allannic H; Fauchet R; Lorcy Y; Heim J; Gueguen M; Leguerrier AM; Genetet B Ann Endocrinol (Paris); 1980; 41(1):70-2. PubMed ID: 6893111 [TBL] [Abstract][Full Text] [Related]
4. HLA and Graves' disease: an association with HLA-DRw3. Allannic H; Fauchet R; Lorcy Y; Heim J; Gueguen M; Leguerrier AM; Genetet B J Clin Endocrinol Metab; 1980 Oct; 51(4):863-7. PubMed ID: 6932402 [TBL] [Abstract][Full Text] [Related]
5. The association of HLA with autoimmune thyroid disease in Newfoundland. The influence of HLA homozygosity in Graves' disease. Farid NR; Barnard JM; Marshall WH Tissue Antigens; 1976 Sep; 8(3):181-9. PubMed ID: 989647 [TBL] [Abstract][Full Text] [Related]
6. The role of HLA antigens in the manifestation and course of Graves' disease. Stenszky V; Kozma L; Balazś C; Bear JC; Farid NR Mol Biol Med; 1986 Feb; 3(1):53-62. PubMed ID: 3485758 [TBL] [Abstract][Full Text] [Related]
7. [Graves' disease. Predominance of the DRw3 antigen (author's transl)]. Allanic H; Fauchet R; Lorcy Y; Heim J; Guéguen M; Leguerrier AM; Genetet B Nouv Presse Med; 1980 Jun; 9(26):1823-6. PubMed ID: 6893077 [TBL] [Abstract][Full Text] [Related]
8. A study of human leukocyte D locus related antigens in Graves' disease. Farid NR; Sampson L; Noel EP; Barnard JM; Mandeville R; Larsen B; Marshall WH; Carter ND J Clin Invest; 1979 Jan; 63(1):108-13. PubMed ID: 105012 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity by cluster analysis techniques of Graves' patients typed for HLA DR and IgG heavy chain markers. Frecker MF; Preus M; Kozma L; Krasrits E; Stenszky V; Balazś C; Farid NR Mol Biol Med; 1986 Feb; 3(1):63-71. PubMed ID: 3083192 [TBL] [Abstract][Full Text] [Related]
11. Thyroid autoimmune disease in a large Newfoundland family: the influence of HLA. Farid NR; Barnard JM; Marshall WH; Woolfrey I; O'Driscoll RF J Clin Endocrinol Metab; 1977 Dec; 45(6):1165-72. PubMed ID: 579351 [TBL] [Abstract][Full Text] [Related]
12. Polymorphism of the fourth component of complement in Graves' disease and type I diabetes mellitus. Skanes V; Larsen B; Sampson-Murphy L; Farid NR Clin Invest Med; 1985; 8(2):126-32. PubMed ID: 3869086 [TBL] [Abstract][Full Text] [Related]
13. Human lymphocyte antigens (HLA) and Graves' disease in Turkey. Orhan Y; Azezli A; Carin M; Aral F; Sencer E; Molvalilar S J Clin Immunol; 1993 Sep; 13(5):339-43. PubMed ID: 7902362 [TBL] [Abstract][Full Text] [Related]
14. HLA-A, -B, -C and -DR antigens in patients with Graves' disease and their correlation with signs and clinical course. Dahlberg PA; Holmlund G; Karlsson FA; Säfwenberg J Acta Endocrinol (Copenh); 1981 May; 97(1):42-7. PubMed ID: 6164233 [TBL] [Abstract][Full Text] [Related]
15. Human lymphocyte antigens in Graves' disease: correlation with persistent course of disease. Baldini M; Pappalettera M; Lecchi L; Orsatti A; Meroni L; Tozzi R; Scalamogna M; Cantalamessa L Am J Med Sci; 1995 Jan; 309(1):43-8. PubMed ID: 7825652 [TBL] [Abstract][Full Text] [Related]
17. HLA antigens and thyroid autoantibodies in patients with Graves' disease and their first degree relatives. Mather BA; Roberts DF; Scanlon MF; Mukhtar ED; Davies TF; Smith BR; Hall R Clin Endocrinol (Oxf); 1980 Feb; 12(2):155-63. PubMed ID: 6893172 [TBL] [Abstract][Full Text] [Related]
18. Failure to demonstrate cell-mediated immune responses to thyroid antigens in Graves' disease using in vitro assays of lymphokine-mediated migration inhibition. Ludgate ME; Ratanachaiyavong S; Weetman AP; Hall R; McGregor AM J Clin Endocrinol Metab; 1985 Jan; 60(1):98-102. PubMed ID: 3871093 [TBL] [Abstract][Full Text] [Related]
19. The interaction of a type A retroviral particle and class II human leukocyte antigen susceptibility genes in the pathogenesis of Graves' disease. Jaspan JB; Sullivan K; Garry RF; Lopez M; Wolfe M; Clejan S; Yan C; Tenenbaum S; Sander DM; Ahmed B; Bryer-Ash M J Clin Endocrinol Metab; 1996 Jun; 81(6):2271-9. PubMed ID: 8964863 [TBL] [Abstract][Full Text] [Related]